387
Views
2
CrossRef citations to date
0
Altmetric
Articles

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy

, , , , , ORCID Icon, , , ORCID Icon, , , , , & ORCID Icon show all
Pages 1942-1948 | Received 11 Jan 2022, Accepted 19 Mar 2022, Published online: 04 Apr 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Khaled Sanber, Kevin Ye, Hua-Ling Tsai, Matthew Newman, Jonathan A. Webster, Ivana Gojo, Gabriel Ghiaur, Gabrielle T. Prince, Lukasz P. Gondek, B. Douglas Smith, Mark J. Levis, Amy E. DeZern, Alexander J. Ambinder, William B. Dalton & Tania Jain. (2023) Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leukemia & Lymphoma 64:4, pages 846-855.
Read now

Articles from other publishers (1)

Phaedon D. Zavras, Ilias Sinanidis, Panagiotis Tsakiroglou & Theodoros Karantanos. (2023) Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. International Journal of Molecular Sciences 24:5, pages 5018.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.